Quick Answer
GOLDENWELL BIOTECH, INC. reported Net Income Loss of -$131.5 thousand for the year ending 2024.
- GOLDENWELL BIOTECH, INC. showed a decrease of -12.0% in Net Income Loss from 2023 to 2024.
- This data is from GOLDENWELL BIOTECH, INC.'s annual report (Form 10-K), filed with the SEC on May 15, 2025.
- XBRL data for this metric is available from 2019 to 2024 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2019: -$2.0 thousand | Q1 2020: -$2.3 thousand | Q2 2020: -$141.00 | Q3 2020: -$879.00 | Q4 2020: -$3.0 thousand | Q1 2021: -$46.1 thousand | Q2 2021: -$23.6 thousand | Q3 2021: -$87.4 thousand | Q4 2021: -$29.5 thousand | Q1 2022: -$33.4 thousand | Q2 2022: -$26.8 thousand | Q3 2022: -$4.6 thousand | Q4 2022: -$920.3 thousand | Q1 2023: -$33.6 thousand | Q2 2023: -$27.1 thousand | Q3 2023: -$35.4 thousand | Q4 2023: -$20.8 thousand | Q1 2024: $31.0 thousand | Q2 2024: $49.9 thousand | Q3 2024: $23.1 thousand | Q1 2025: -$34.4 thousand | Q2 2025: -$5.2 thousand | Q3 2025: -$8.0 thousand.
- Over the full 6 years of available data (2019 to 2024), GOLDENWELL BIOTECH, INC.'s Net Income Loss has declined by 5,590.1%.
- Historical annual values: Fiscal year 2024: -$131.5 thousand | Fiscal year 2023: -$117.4 thousand | Fiscal year 2022: -$985.1 thousand | Fiscal year 2021: -$117.0 thousand | Fiscal year 2020: -$6.3 thousand | Fiscal year 2019: -$2.3 thousand.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: